Introduction
Almost two decades ago, it was found that a group of chemotactic cytokines specifically triggers the migration of leukocytes [1] . The expanding numbers of chemokines and their complex interactions with chemokine receptors (both referred to as chemokine mediators in this review) set off broad research activities in all areas of medicine. Meanwhile, industry has taken over to develop chemokine antagonism as a novel therapeutic concept for inflammatory diseases. While clinical trials with chemokine and chemokine receptor antagonists are ongoing [2] , research in the field of chemokine biology remains an area of unexpected discoveries. This review raises and discusses a number of open questions that may help to plan and interpret chemokine research in the context of renal inflammation. or along the progression of experimental kidney disease in rodents. For example, the monocyte chemoattractant protein (MCP)-1/CCL2 has consistently been shown to be secreted by proximal tubular epithelial cells of proteinuric mice, rats and humans [3] . These observations correlated with chemokine receptor CCR2+ macrophage and T cell infiltrates in adjacent interstitial areas. As such, it was predicted that the known function of MCP-1/CCL2 to trigger the recruitment of CCR2+ macrophages and T cells in in vitro assays would translate to experimental renal inflammation, a prediction confirmed by numerous interventional studies in rodents [3, 4] . CCR5 is also present on monocytes and T cells and was shown to specifically mediate leukocyte spreading in flow chamber experiments. Thus, it was predicted that CCR5 would also contribute to the renal recruitment of CCR5+ macrophages and T cells. However, interstitial macrophage and T cell recruitment turned out to be independent of CCR5, at least in mice with renal interstitial fibrosis [5] . In addition, two CCR5 antagonists, AOP-RANTES and Met-RANTES, did not affect interstitial leukocyte recruitment in the same model (own unpubl. data). Moreover, lack of CCR5 rather increased interstitial leukocyte numbers and renal injury in murine crescentic glomerulonephritis via increased expression of CCL3 and CCL5 [6] . These two CC chemokines mediate the recruitment of T cells via CCR1, as such CCR1-deficient mice show altered macrophage and T cell recruitment into the tubulointerstitial compartment after unilateral ureteral obstruction [5] or in crescentic glomerulonephritis [7] . Hence, expression studies may suggest, but not always predict the functional role of chemokine mediators in experimental renal inflammation. A possible explanation for this phenomenon is that multiple chemokine receptors are present on the surface of infiltrating leukocytes and some of them may shuttle passively into the kidney without being functionally involved in the recruitment process. Still, they will be detectable by descriptional expression studies, e.g. transcriptome analysis or immunostaining. Wheth er a single molecule has a functional role for recruitment or not can only be answered by blocking the function of the factor of interest, e.g. by appropriate antagonists. In order to obtain reliable results, it is necessary that such compounds have sufficient species specificity, selectively inhibit the target molecule, and are administered at an appropriate dose based on compound-specific pharmacokinetics and pharmacodynamics in the species studied [8] .
Why Does Chemokine Antagonism Only Partially Reduce Renal Leukocyte Counts?
Although considerable redundancy of single chemokine mediators was initially suspected, many interventional studies revealed that specific antagonists of single chemokine mediators can have significant effects on leukocyte recruitment to diseased tissues. Such data supported the concept that at least some mediators have predominant roles in certain disease entities. On the other hand, data from different groups using various methodological approaches documented that blocking a single chemokine mediator never entirely abrogated leukocyte recruitment. For example, MCP-1/CCL2 or CCR2 blockade both reduced glomerular or interstitial macrophage numbers by approximately 50%, no matter what dose or treatment duration was applied [3, 4] . Three potential explanations have been discussed: (1) redundancy of single chemokine mediators, (2) local leukocyte proliferation which affects tissue leukocyte numbers independent of influx of circulating cells, and (3) variable leukocyte phenotypes with variable expression patterns of chemokine receptors. It is now becoming clear that probably all three mechanisms limit the ability of chemokine antagonism to reduce tissue leukocyte numbers near to zero. Especially the evolving concept of macrophage heterogeneity and phenotypic flexibility in changing cytokine microenvironments offers fascinating perspectives either to explain the aforementioned phenomenon or to learn more about how to specifically modulate renal inflammation [9] . For example, classically activated macrophages of a proinflammatory phenotype express CCR2 on the surface, and alternatively activated macrophages with a wound-healing anti-inflammatory capacity lack CCR2 expression. In this regard, MCP-1/CCL2 and CCR2 blockade may selectively inhibit the influx of monocytes with a predominant proinflammatory phenotype, and may not affect those macrophage phenotypes with predominant immunoregulatory or anti-inflammatory functions. In addition, leukocytes with antiinflammatory properties also recruit to the kidney, e.g. NKT cells [10] and regulatory T cells [11] . Blocking the recruitment of these cells may also explain unexpected outcomes of renal disease models in chemokine receptor knockout mice or mice treated with chemokine antagonists [6, 7, 10] . The aforementioned concept would suggest that strategies targeting two or more chemokines attracting identical leukocyte subsets may not necessarily elicit additive effects on leukocyte counts or tissue damage. The same would apply for chemokine receptors that are coexpressed by the same cell type and share redundant functions. Some of our own unpublished data seem to support this hypothesis. Simultaneous blockade of CCR2 and CCR5 was not superior to MCP-1/CCL2 inhibition in terms of reducing glomerular macrophage counts and glomerular scaring in a murine model of glomerulosclerosis. In contrast, combined chemokine antagonism may be more likely to have additive effects on tissue damage when different disease pathomechanisms are targeted. In view of the suspected role of regulatory and woundhealing macrophage phenotypes for the progression of chronic glomerulopathies and interstitial fibrosis, it will become very important to identify the chemokines that mediate recruitment of these macrophage subclasses into the kidney. Thus, antagonist combinations that simultaneously prevent the recruitment of proinflammatory as well as profibrotic leukocyte subsets have the potential for additive therapeutic effects. It may also be important to develop different strategies for acute or chronic renal inflammation as wound-healing leukocyte phenotypes may either support the resolution of renal inflammation, e.g. in the healing phase of acute tubular necrosis [12] , or facilitate interstitial fibrosis in chronic kidney disease.
What Are the Roles of Homeostatic Chemokines in the Kidney?
Not much is known about the roles of the homeostatic chemokines in the kidney because these are thought to mainly orchestrate the migration to and the spatial distribution within lymphoid organs and bone marrow. For example, B cell-attracting chemokine-1/ CXCL13 and its receptor CXCR5, physiologically orchestrating B cell homing in lymph nodes, is also associated with renal B cell infiltrates and clusters in lupus nephritis and renal vasculitis [13] . As another example, stromal cell-derived factor (SDF)-1/CXCL12 mediates stem cell-homing in the bone marrow but also recruits mesenchymal progenitor cells to the postischemic kidney [14] . CXCR4 blockade can also prevent chronic lupus-like glomerulonephritis in MRLlpr mice, but the contribution of intrarenal SDF-1/CXCR12 expression in this model remains unclear [15] . We have recently discovered that glomerular SDF-1/CXCL12 expression derives from podocytes in db/db mice with type 2 diabetes and that SDF-1/CXCL12 antagonism can prevent diabetic glomerulosclerosis without affecting glomerular leukocyte numbers [16] . Such data indicate that as yet unknown functions of chemokines remain to be discovered and that these may reveal novel pathomechanisms and therapeutic targets in kidney disease. To further extend the aforementioned concept of chemokine coblockade, it might be more effective to simultaneously target proinflammatory and homeostatic chemokines rather than different members of the same group. However, experimental data to support this hypothesis are not yet available in the public domain.
What Are the Roles of Atypical, Nonsignaling Chemokine Receptors?
Some 'atypical' chemokine receptors do not mediate intracellular calcium ion mobilization upon binding of their chemokine ligands, i.e. the Duffy antigen/receptor of chemokines (DARC), D6, the chemocentryx chemokine receptor (CCX-CKR), and CXCR7 [17] . The atypical receptors share alterations in the canonical DRYLAIF motif which mediates G-protein coupling in all other chemokine receptors. DARC binds several inflammatory CC and CXC chemokines, D6 binds to almost all proinflammatory and homeostatic CC chemokines, CCX-CKR binds the homeostatic chemokines ELC/CCL19, SLC/CCL21, and TECK/CCL25, and CXCR7 binds I-TAC/CXCL11 and SDF-1/CXCL12 [17, 18] . There is emerging evidence that atypical chemokine receptors regulate chemokine functions, e.g. by binding, internalization and intracellular degradation like other functional decoys and scavenger receptors. Dependent on their cell-, organ-and context-specific expression, the atypical receptors can negatively regulate chemokine signals, and hence, control bioavailable chemokine levels in a particular microenvironment to influence the recruitment of inflammatory cells to that site. Current experimental data suggest that D6, CCX-CKR, and CXCR7 act as scavengers for their respective ligands, with D6 mainly reducing local levels of inflammatory chemokines, and CCX-CKR regulating homeostatic chemokine concentrations [18] . DARC internalizes chemokines from the basolateral cell surface of vascular endothelial cells. Interestingly, this e36 does not lead to degradation, but DARC mediates chemokine transcytosis, leading to increased apical retention of intact chemokines, increased presentation of these chemokines to leukocytes and enhanced leukocyte migration across monolayers [19] . Together with the known expression of DARC on high endothelial venules of lymph nodes and postcapillary venules, i.e. sites of leukocyte extravasation, these data suggest that DARC internalizes and transports tissue-derived inflammatory chemokines onto the luminal endothelial cell surface where they enhance local leukocyte recruitment. In inflamed kidneys, expression of DARC is induced in interstitial endothelial cells. Consistently, DARC deficiency ameliorated disease in two neutrophil-dependent models of acute renal injury [20] . However, in renal disease models with a predominant infiltration of renal macrophages and T cells, DARC deficiency did not improve renal inflammation. In contrast, renal leukocyte infiltrates were increased in DARC-deficient mice at early time points, accelerating renal injury without affecting outcomes in the later disease phase [21] . These results suggest that DARC expressed on interstitial endothelial cells contributes to renal neutrophil recruitment, but its role is redundant for the infiltration of macrophages and T cells. Nevertheless, In the early days of chemokine research, antagonists were generated by different technical approaches like neutralizing antibodies to chemokines and chemokine receptors as well as truncated, mutated or modified chemokine proteins. Some chemokine receptor antibodies or modified chemokines were found to elicit partial agonistic effects which compromised the interpretation of the data. Although most companies favored the development of small molecule receptor antagonists, neutralizing antibodies are among those compounds currently tested in clinical trials ( table 1 ) . Other technologies like small peptide-based receptor inhibitors or RNAse-resistant RNA aptamers are still in preclinical development. Meanwhile, chemokine receptor antagonists blocking CCR5 or CXCR4 have been approved for therapy in human HIV infection and stem cell transplantation, respectively ( table 1 ) . Their lack of efficacy, e.g. in multiple sclerosis or rheumatoid arthritis studies, has dampened the initial enthusiasm regarding their therapeutic potential in chronic inflammatory disease [2] . This may be a result of oversimplifying concepts on chemokine biology in the early days. Thus, more research is required to identify appropriate antagonistic strategies to control inflammation and tissue remodeling in clearly defined disease contexts. The availability of specific antagonists should help experimental nephrologists, provided that the compounds are suitable for the model species from a pharmacodynamic point of view.
Summary and Perspective
The role of chemokine mediators in experimental kidney disease remains an attractive research field holding the potential for unexpected discoveries in the future. We need to identify how specific leukocyte subpopulations like immunoregulatory macrophages, B cells, Th17 cells, regulatory T cells, and the different types of renal progenitor cells recruit to the different renal compartments during the different phases of acute and chronic nephropathies. In addition, we need to learn more about the roles of the homoeostatic chemokines and the atypical chemokine receptors in inflammatory renal disease to identify new therapeutic strategies based on these molecules.
